<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00525005</url>
  </required_header>
  <id_info>
    <org_study_id>HMC-HO-GI-0701</org_study_id>
    <nct_id>NCT00525005</nct_id>
  </id_info>
  <brief_title>Docetaxel, Oxaliplatin and S-1 (DOS) for Advanced Gastric Cancer</brief_title>
  <official_title>A Phase II Study of Docetaxel, Oxaliplatin and S-1 (DOS) in Patients With Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hallym University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of combination of docetaxel,
      oxaliplatin, and S-1 (DOS) in the treatment of advanced gastric cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Docetaxel is an anti-microtubule agent. Docetaxel is an active agent for gastric cancer, with
      response rate (RR) of 20-24% as a single agent and RR of 37-40% as a combination therapy with
      5-FU and/or cisplatin.

      S-1 is a new oral dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine (DIF). In
      two late phase II studies of S-1 for advanced gastric cancer, RR was 45%, with very low (2%)
      incidence of grade 3 toxicity.

      Recent phase I/II trial of the combination of docetaxel and S-1 in patients with advanced
      gastric cancer suggests that repeated 3-4 week cycles of S-1 60-80mg/m2 /day for 14 days
      combined with docetaxel 40-75mg/m2 is feasible.

      Oxaliplatin, diaminocyclohexane-platinum, is an alkylating agent inhibiting DNA replication.
      Comparing to cisplatin or carboplatin, oxaliplatin appear to be more effective and has a more
      favorable toxicity profile. Phase II studies of the combination of docetaxel and oxaliplatin
      in patients with advanced gastric cancer suggests that docetaxel 60 or 75mg/m2 combined with
      oxaliplatin 130 or 80mg/m2 every 3 weeks is feasible.

      Recent dose finding study of the combination of docetaxel, oxaliplatin and S-1 (DOS) in
      patients with advanced gastric cancer suggests that docetaxel 52.5mg/m2 on day 1 and
      oxaliplatin 105mg/m2 on day 1 combined with S-1 80mg/m2 on day1 to day 14 every 3 weeks is
      feasible.

      Docetaxel, S-1 and oxaliplatin have distinct mechanisms of action and no overlapped key
      toxicities. Furthermore, fluoropyrimidine and docetaxel or oxaliplatin have shown synergism
      in vivo studies and in clinical trials. Based on these results, the combination of DOS is a
      reasonable candidate of new chemotherapeutic regimen for the advanced gastric cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>2.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety, progression-free survival, and overall survival</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Stomach Neoplasms</condition>
  <arm_group>
    <arm_group_label>DOS (Docetaxel, Oxaliplatin and S-1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOS (Docetaxel, Oxaliplatin and S-1)</intervention_name>
    <description>Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period)</description>
    <arm_group_label>DOS (Docetaxel, Oxaliplatin and S-1)</arm_group_label>
    <other_name>Taxotere</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>TS-1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed gastric adenocarcinoma, initially diagnosed or recurred

          -  Unresectable, locally advanced or metastatic

          -  At least one uni-dimensional measurable lesion by RECIST criteria

          -  Age 18 to 70 years old

          -  ECOG performance status ≤2

          -  Estimated life expectancy ≥3 months

          -  Adequate bone marrow function (WBCs ≥4,000/µL or absolute neutrophil count ≥1,500/µL,
             platelets ≥100,000/µL),

          -  Adequate kidney function (creatinine &lt;1.5 mg/dL)

          -  Adequate liver function (bilirubin ≤1.8 mg/dL, transaminase levels &lt;2 times the upper
             normal limit

          -  Written informed consent

        Exclusion Criteria:

          -  Other tumor type than adenocarcinoma

          -  Previous history of chemotherapy (exception: adjuvant chemotherapy)

          -  Presence of CNS metastasis, psychosis, or seizure

          -  Obvious bowel obstruction

          -  Evidence of serious gastrointestinal bleeding

          -  Peripheral neuropathy (NCI CTC &gt;= Grade I)

          -  Past or concurrent history of neoplasm other than gastric adenocarcinoma, except for
             curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix uteri

          -  Pregnant or lactating women, women of childbearing potential not employing adequate
             contraception

          -  Other serious illness or medical conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dae Young Zang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hallym University Medical Center</name>
      <address>
        <city>Anyang</city>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Yamaguchi K, Shimamura T, Hyodo I, Koizumi W, Doi T, Narahara H, Komatsu Y, Kato T, Saitoh S, Akiya T, Munakata M, Miyata Y, Maeda Y, Takiuchi H, Nakano S, Esaki T, Kinjo F, Sakata Y. Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer. 2006 Jun 19;94(12):1803-8.</citation>
    <PMID>16773074</PMID>
  </reference>
  <reference>
    <citation>Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Gotoh M, Sakamoto J, Nishiyama M. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3402-7.</citation>
    <PMID>16740764</PMID>
  </reference>
  <reference>
    <citation>Zang DY, Yang DH, Lee HW, Hwang SW, Song HH, Jung JY, Kwon JH, Kim HJ, Kim JH, Park SR, Kim MJ, Jang KM, Park CK, Kim JH, Lee BH. Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age. Cancer Chemother Pharmacol. 2009 Feb;63(3):509-16. doi: 10.1007/s00280-008-0768-9. Epub 2008 May 15.</citation>
    <PMID>18481067</PMID>
  </reference>
  <reference>
    <citation>Richards D, Wilfong L, Sborov M, McCollum D, Khan M, Boehm K, Zhan F. Phase II trial of docetaxel+oxaliplatin in advanced gastroesophageal and/or stomach cancer. 7th World Congr Gastrointest cancer. 2005: Abs: P-143</citation>
  </reference>
  <reference>
    <citation>Schinzari G, D'Argento E, Quirino M, Basso M, Trigila N, Di Leonardo G, Cassano A, Pozzo C, Barone C. Docetaxel and oxaliplatin combination as second-line treatment in patients with advanced gastric cancer. J Clin Oncol. 2005 Jun 1;23(16S Pt1 Suppl):354s, Abs:4188</citation>
  </reference>
  <reference>
    <citation>Zang D, Yang D, Lee H, Lee B, Hwang S, Kim H, Song H, Jung J, Kim J, Kwon J. Phase I study of docetaxel, oxalipaltin and S-1 (DOS) for patients with advanced gastric cancer. Ann Oncol 2007 Sep 23; Abs:in press</citation>
  </reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2007</study_first_submitted>
  <study_first_submitted_qc>September 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2007</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stomach Neoplasm</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>S-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

